
{{Drugbox|Verifiedfields=changed|legal_CA=<!-- Schedule I, II, III, IV, V, VI, VII, VIII -->|DrugBank_Ref={{drugbankcite|correct|drugbank}}|PubChem=|ATC_supplemental={{ATC|J07|AH02}} {{ATC|J07|AH03}} {{ATC|J07|AH04}} {{ATC|J07|AH05}} {{ATC|J07|AH06}} {{ATC|J07|AH07}} {{ATC|J07|AH08}} {{ATC|J07|AH09}}|ATC_suffix=AH01|ATC_prefix=J07|CAS_number=|CAS_number_Ref={{cascite|correct|??}}|ChemSpiderID=none|ChemSpiderID_Ref={{chemspidercite|changed|chemspider}}|routes_of_administration=Intramuscular (conjugate), Subcutaneous (polysaccharide)
<!-- Identifiers -->|legal_status=|legal_US=Rx-only|legal_UK=<!-- GSL, P, POM, CD, or Class A, B, C -->|legal_AU=<!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled -->|Watchedfields=changed|INN_EMA=Meningococcal group B|licence_EU=yes|pregnancy_category=|pregnancy_US=C|pregnancy_AU=B2|MedlinePlus=a607020|Drugs.com={{drugs.com|monograph|meningococcal_vaccine}}|tradename=Menactra, Menveo, Menomune, Others|vaccine_type=Conjugate or polysaccharide
<!-- Clinical data -->|target=[[Neisseria meningitidis]] <!-- the antigen to protect against -->|type=vaccine|image=<!-- Vaccine data -->|verifiedrevid=445667873|DrugBank=<!-- Chemical data -->}}
{{Drugbox|Verifiedfields=changed|legal_UK=<!-- GSL, P, POM, CD, or Class A, B, C -->|DrugBank_Ref={{drugbankcite|correct|drugbank}}|PubChem=|ATC_supplemental={{ATC|J07|AH02}} {{ATC|J07|AH03}} {{ATC|J07|AH04}} {{ATC|J07|AH05}} {{ATC|J07|AH06}} {{ATC|J07|AH07}} {{ATC|J07|AH08}} {{ATC|J07|AH09}}|ATC_suffix=AH01|ATC_prefix=J07|CAS_number=|CAS_number_Ref={{cascite|correct|??}}|ChemSpiderID=none|ChemSpiderID_Ref={{chemspidercite|changed|chemspider}}|routes_of_administration=Intramuscular (conjugate), Subcutaneous (polysaccharide)
<!-- Identifiers -->|legal_status=|legal_US=Rx-only|legal_CA=<!-- Schedule I, II, III, IV, V, VI, VII, VIII -->|Watchedfields=changed|legal_AU=<!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled -->|pregnancy_category=Category C|pregnancy_US=<!-- A / B            / C / D / X -->|pregnancy_AU=<!-- A / B1 / B2 / B3 / C / D / X -->|MedlinePlus=a607020|Drugs.com={{drugs.com|monograph|meningococcal_vaccine}}|tradename=Menactra, Menomune, MenAfriVac, Other|vaccine_type=Conjugate or polysaccharide
<!-- Clinical data -->|target=[[Neisseria meningitidis]] <!-- the antigen to protect against -->|type=vaccine|image=<!-- Vaccine data -->|verifiedrevid=445667873|DrugBank=<!-- Chemical data -->}} <!-- Definition and medical uses --> '''Meningococcal vaccine''' refers to any of the [[Vaccine|vaccines]] used to prevent infection by ''[[Neisseria meningitidis]]''.<ref name="WHO20112">{{cite journal|title=Meningococcal vaccines: WHO position paper|journal=Weekly epidemiological record|date=Nov 2011|volume=47|issue=86|page=521-540|pmid=22128384|url=http://www.who.int/wer/2011/wer8647.pdf}}</ref> Different versions are effective against some or all of the following types of meningococcus: A, C, W135, and Y.<!-- <ref name=WHO2011/> --> The vaccines are between 85 and 100% effective for at least two years.<ref name="WHO20112" /> They result in a decrease in [[meningitis]] and [[sepsis]] among populations were they are widely used.<ref>{{cite journal|last1=Patel|first1=M|last2=Lee|first2=CK|title=Polysaccharide vaccines for preventing serogroup A meningococcal meningitis.|journal=The Cochrane Database of Systematic Reviews|date=25 January 2005|issue=1|pages=CD001093|pmid=15674874}}</ref><ref>{{cite journal|last1=Conterno|first1=LO|last2=Silva Filho|first2=CR|last3=RÃ¼ggeberg|first3=JU|last4=Heath|first4=PT|title=Conjugate vaccines for preventing meningococcal C meningitis and septicaemia.|journal=The Cochrane Database of Systematic Reviews|date=19 July 2006|issue=3|pages=CD001834|pmid=16855979}}</ref> They are given either by [[Intramuscular|injection into a muscle]] or [[Subcutaneous injection|just under the skin]].<ref name="WHO20112" /><!-- Recommendations -->The [[World Health Organization]] recommends that countries with a moderate or high rate of disease or with frequent outbreaks should [[Vaccination schedule|routinely vaccinate]].<ref name="WHO20112" /><ref name="WHO2015A">{{cite journal|title=Meningococcal A conjugate vaccine: updated guidance, February 2015.|journal=Weekly epidemiological record|date=20 Feb 2015|volume=8|issue=90|page=57-68|pmid=25702330|url=http://www.who.int/wer/2015/wer9008.pdf}}</ref> In countries with a low risk of disease, they recommend that high risk groups should be immunized.<ref name="WHO20112" /> In the [[African meningitis belt]] efforts to immunize all people between the ages of one and thirty with the meningococcal A [[conjugate vaccine]] are ongoing.<ref name="WHO2015A" /> In Canada and the United States the vaccines effective against all four types are recommended routinely for teenagers and others who are at high risk.<ref name="WHO20112" /> They are also required for people travelling to [[Mecca]] for [[Hajj]].<ref name="WHO20112" /><!-- Safety and formulations -->

Safety is generally good.<!-- <ref name=WHO2011/> --> Some develop pain and redness at the site of injection.<ref name="WHO20112" /> Use in pregnancy appears to be safe.<ref name="WHO2015A" /> [[Anaphylaxis|Severe allergic reactions]] occur in less than one in a million doses.<ref name="WHO20112" /><!-- Society and culture -->The first meningococcal vaccine became available in the 1970s.<ref>{{cite book|last1=Barrett|first1=Alan D.T.|title=Vaccinology : an essential guide|date=2015|isbn=9780470656167|page=168|url=https://books.google.ca/books?id=NvKyBwAAQBAJ&pg=PA168}}</ref> It is on the [[World Health Organization's List of Essential Medicines]], the most important medication needed in a basic [[health system]].<ref>{{cite web|title=WHO Model List of EssentialMedicines|url=http://apps.who.int/iris/bitstream/10665/93142/1/EML_18_eng.pdf?ua=1|work=World Health Organization|accessdate=22 April 2014|date=October 2013}}</ref> The wholesale cost is between 3.23 and 10.77 USD per dose as of 2014.<ref>{{cite web|title=Vaccine, Meningococcal|url=http://erc.msh.org/dmpguide/resultsdetail.cfm?language=english&code=MENV&s_year=2014&year=2014&str=&desc=Vaccine%2C%20Meningococcal&pack=new&frm=VIAL&rte=INJ&class_code2=19%2E3%2E&supplement=&class_name=%2819%2E3%2E%29Vaccines%3Cbr%3E|website=International Drug Price Indicator Guide|accessdate=6 December 2015}}</ref> In the United States it costs 100 to 200 USD for a course.<ref name="Ric2015">{{cite book|last1=Hamilton|first1=Richart|title=Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition|date=2015|publisher=Jones & Bartlett Learning|isbn=9781284057560|page=315}}</ref>

== References ==
<references />
